Search Results - jun+liu

6 Results

Sort By:

Combination therapy targets intrinsic cancer resistance to nucleoside DNA methyltransferase inhibitors.

Unmet NeedGenome stability is regulated by a variety of mechanisms. One such mechanism is DNA methylation. DNA methylation can alter the manner in which genes are expressed, and aberrations in methylation management are well documented as features of cancer cells. DNA methylation is regulated in part by enzymes known as DNA methyltransferases (DNMTs)....

Published: 6/28/2024 | Inventor(s): Srinivasan Yegnasubramanian, Jianyong Liu, William Nelson, Jun Liu

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Technology Classifications, Technology Classifications > Therapeutic Modalities > Small Molecules

Non-immunosuppressive FK506 analogs and use thereof

Unmet NeedChronic, nonhealing wounds are estimated to affect approximately 2% of the general population, and the cost of caring for these wounds exceeds $50 billion per year. These costs are expected to rise due to the increasing prevalence of diabetes and other diseases that hinder wound healing. Chronic infections increase morbidity and mortality...

Published: 6/28/2024 | Inventor(s): Jun Liu, Zhaoli Sun, Brandon Peiffer, Yuefan Wang, Le Qi, Zufeng Guo, Hanjing Peng, Ali Ahmadi

Keywords(s): Antagonists/Inhibitors, Combination, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutic Substance Synthesis Method, Therapeutics, Therapy Type, Transplants

Category(s): Clinical and Disease Specializations > Wound Healing, Technology Classifications > Therapeutic Modalities > Small Molecules

Use of AHR Agonists to Prevent or Treat NEC in Premature Infants

UNMET NEED: Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease in premature infants. The main risk factors for the development of NEC are prematurity, bacterial colonization and administration of formula feeds, which in the setting of an abnormal microbiome lead to enhanced signaling via toll like receptor 4...

Published: 6/27/2024 | Inventor(s): David Hackam, Chhinder Sodhi, Jun Liu, Peng Lu

Keywords(s): Agonists/Promoters, Disease Indication, Gastrointestinal Disorders, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Itraconazole Analogs and Use Thereof

C11669: Novel Compounds for Cancer and Macular Degeneration TreatmentNovelty: This invention is a series of novel and potent itraconazole derivative that have showed strong activity against tumor growth and macular degeneration.Value Proposition: The novel compounds effectively inhibit angiogenesis, which is critical for tumor growth and macular degeneration....

Published: 6/27/2024 | Inventor(s): Jun Liu, Wei Shi, Kalyan Kumar Pasunooti, Wukun Liu, Ruojing Li, Sarah Head, Yingjun Li

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Eye Disorders, Macular Degeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration

Methionine Aminopeptidases from Mycobacterium Tuberculosis as Novel Antimycobacterial Targets: I. Cloning, Over-expression, and Purification of Methionine Aminopeptidases from Mycobacterium Tuberculosis. II. Discovery of Inhibitors of M. Tuberculos

C10796: Novel Antimycobacterial Targets Value Proposition: • Promising target for the development of new antibiotics. • Compounds that inhibit the growth of mycobacteria in culture. • Plasmids containing MetAP genes can be used to generate protein for anti-tuberculosis drug screening. Technical Details: Infectious diseases are the second...

Published: 6/27/2024 | Inventor(s): Jun Liu, Shridhar Bhat, Omonike Olaleye

Keywords(s): Antagonists/Inhibitors, Bacterial Infections, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Infectious Diseases, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Target-based Screening Tool, Therapeutic Matter, Therapeutic Substance, Therapeutics, Tuberculosis, Tuberculosis (TB)

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases > Bacterial Infections, Clinical and Disease Specializations > Infectious Diseases > Tuberculosis, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Technology Classifications > Research Tools

Potent, Simplified Derivatives of Immunosuppressive Agents

C04420: Potent, Simplified Derivatives of Immunosuppressive Agents Technical Details: Pateamine A (PatA), a metabolite from the marine sponge Mycale, is a potent inhibitor of the intracellular signal transduction pathway that emanates from the T-cell receptor and leads to the transcription of cytokines such as interleukin-2 (IL-2). Researchers at...

Published: 6/27/2024 | Inventor(s): Daniel Romo, Nam Song Choi, Zonggao Shi, Jun Liu, Woon-Kai Low, Yongjun Dang, Tilman Schneider-Poetsch

Keywords(s): Antagonists/Inhibitors, Cancers, Disease Indication, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics